Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.77 |
| ▸ | RAB9A | P51151 | 12/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.77 |
| ▸ | MAPT | P10636 | 8/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.77 |
| ▸ | PKM | P14618 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.70 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.70 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.70 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 4/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.60 |
| ▸ | ATP4A | P20648 | 1/20 | 0.54 |
| ▸ | ATP4B | P51164 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8548385 | 1.00 | NPC1 (0.77) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL8551153 | 0.87 | NPC1 (1.00) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL8548400 | 0.86 | KDM4E (0.79) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL8548399 | 0.86 | KDM4E (0.79) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL8549677 | 0.85 | NPC1 (0.77) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL8593016 | 0.85 | NPC1 (0.56) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL8593013 | 0.85 | NPC1 (0.56) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL8549678 | 0.85 | NPC1 (0.77) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL8548490 | 0.82 | RAB9A (1.00) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL8548487 | 0.82 | RAB9A (1.00) | NPC1RAB9AKDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2016115360-A1 | C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| EP-0830345-A1 | STYRYL BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1996039391-A1 | STYRYL BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | NPC1 1443/4885RAB9A 1223/4885KDM4E 4652/4885 |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | NPC1 1443/4885RAB9A 1223/4885KDM4E 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.